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DNA Ploidy Analysis 
for the Detection of Minimal Residual Disease 
in Acute Lymphoblastic Leukemia 
Barton C. Kenney, Arthur Zieske, and Brian R. Smith. 
Section of Hematopathology, Department of Laboratory Medicine, 
Yale University, School of Medicine, New Haven, CT 
The detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) has clear 
prognostic implications, as MRD-positivity during or after induction chemotherapy is associated with poor 
outcome and increased risk of leukemic relapse. However, the detection of MRD in B-lineage ALL by 
flow cytometric immunophenotyping can be difficult in the post-therapy bone marrow, due to an increase 
in normal B-cell precursors that can be confused with leukemic blasts. The aim of this study was to assess 
whether flow cytometric DNA ploidy analysis, in tandem with flow cytometric immunophenotyping, can 
be used as a sensitive means of detecting residual or relapsed ALL in patients with previously documented 
aneuploid cell populations. We retrospectively studied all cases of ALL at our institution over a 12 year 
period from 1991-2003 (n=l 14). Aneuploid clonal populations were present in 32% of patients (n=37). Of 
this group, 24 had “normal” immunophenotypes, as defined by phenotypic similarity of the leukemic clone 
with normal precursor B-cells, and 13 had “aberrant” immunophenotypes predominantly manifest as 
simultaneous expression of myeloid markers. Aneuploidy detected the presence of residual or relapsed 
disease in all cases where disease was found by flow immunophenotyping (normal n=8; aberrant n=7). In 
the group with normal immunophenotype, aneuploidy detected post-remission disease in three patients and 
MRD in one patient in whom the diagnosis could not be made with confidence by immunophenotyping. In 
the aberrant group, aneuploidy detected MRD in two patients in whom immunophenotyping failed to show 
positivity, likely because of downregulation of myeloid antigens on leukemic blasts. These results suggest 
that flow cytometric DNA ploidy analysis may be a useful and sensitive adjunct in determining relapse or 
presence of MRD in patients with B-lineage ALL. 
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Acute Leukemias are the leading cause of cancer death in the United States among individuals 
under 35 years of age. Affecting over 4000 people each year, and comprising more than 23% of all cancers 
in children under age fifteen, Acute Lymphoblastic Leukemia (ALL) in particular is a significant oncologic 
threat.1'2 With the evolution of hematology and the advent of molecular diagnostics and flow cytometric 
immunophenotyping, diagnosis and classification of the acute leukemias has become a detailed and precise 
endeavor. This diagnostic revolution has not spared ALL, in which T- and B-cell lineage, clonality, stage 
of maturation, DNA content, cytogenetic abnormality, and specific immunophenotype can be determined 
rapidly and reliably using modem laboratory methods. Precise diagnosis has been paralleled by the 
formulation of effective treatment regimens, leading to an impressive success rate in achieving complete 
clinical remission using modem multi-agent chemotherapeutic protocols. Improved therapy has resulted in 
the redefinition of ALL from a nearly incurable disease to one with a 5-year survival rate of up to 80% for 
children younger than 15 years of age/'3 However, the fact remains that approximately 25 to 30% of 
children and 70% of adults with ALL will experience a relapse of their disease.6'8 With this issue arises the 
need for early detection of recurrence and prognostic or risk-stratification based on the presence of post¬ 
therapy residual leukemia. 
As the sensitivity of laboratory techniques has escalated, the concept of minimal residual disease 
(MRD) has emerged. In general terms, MRD is the presence of leukemia in a specimen the analysis of 
which by morphologic means alone would not demonstrate disease. The detection of MRD has been 
shown to be a significant prognostic factor in the outcome of patients with ALL.6’8'16 The presence of 
MRD at various intervals during and after induction chemotherapy predicts relapse, and multiple studies 
have found that outcome is quantitatively related to the level of MRD at a given time interval.8'10 This 
prognostic power is sustained even when controlling for other known prognostic variables, and it has been 
suggested that MRD levels may be useful for risk-stratification of patients into more or less intensive 
treatment groups when used as an indicator of response to therapy. Such risk-grouping could potentially 
save rapid responders from chemotherapy-associated morbidity and mortality while simultaneously giving 
poor responders a better chance at remission with intensified therapy.12,14 
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Multiple techniques have been employed to detect MRD in ALL, beginning with light microscopy 
of bone marrow specimens, cytogenetics, and fluorescence in-situ hybridization (FISH) against leukemia- 
associated genetic targets. With time, significantly more sensitive methods have been developed to detect 
residual leukemic clonal populations, including flow cytometric immunophenotyping and polymerase chain 
reaction (PCR) amplification of antigen receptor genes or chromosomal translocations. These more 
recently developed techniques provide sensitivities several orders of magnitude greater than that of 
traditional methods.17 Despite their enormous power, the optimal use of these techniques is not completely 
established, and each has its own strengths and limitations. Flow cytometric assays maintain the 
advantages of rapidity, cost-effectiveness, and freedom from dependence on pre-identified genetic 
alterations in the leukemic clone. Additionally, the literature has clearly shown flow cytometric 
immunophenotyping of post-remission bone marrow specimens to be predictive of outcome in ALL.b 14 
Therefore, many institutions, including our own, choose to rely on this technology. However, flow 
cytometry has its disadvantages as well. One problem of interest is that detection of MRD can be obscured 
by the presence of normal precursor B-cells (hematogones), which are often present in increased numbers 
in post-therapeutic bone marrow.18'19 This issue becomes especially salient when the leukemic clone does 
not possess a unique and distinguishing immunophenotype. The decreased specificity of 
immunophenotyping in this circumstance implies the need for an adjunctive diagnostic criterion in order to 
maintain analytical power. 
DNA ploidy of leukemic cells has historically been a well-recognized prognostic factor in 
childhood ALL. Hyperdiploid karyotypes, defined by the presence of 51 to 65 chromosomes or a DNA 
index (DI) of 1.16 to 1.6, are associated with an improved outcome.20'21 Conversely, hypodiploid 
karyotypes with less than 46 chromosomes are harbingers of a poor outcome.22'24 Consequently, flow 
cytometric methods are employed to measure the Dl of diagnostic marrow specimens in order to identify 
aneuploid cell populations for the purposes of prognostication. However, the use of flow cytometric DNA 
ploidy studies for the detection of recurrent disease or MRD in ALL has not been explored in the literature. 
In patients with a documented aneuploid leukemic cell population at diagnosis, marrow analysis for DNA 
ploidy may provide a sensitive means of detecting the re-emergence or persistence of a leukemic clone. 
This would provide especially useful information for patients with B-lineage ALL clones that happen to 

lack aberrant immunophenotypes. A combined approach of ploidy and immunophenotypic studies has 
been shown to be effective in detecting MRD in one study of patients with multiple myeloma.25 With a 
significant number of ALL patients harboring aneuploid cell populations at diagnosis as well, this method 
may be applicable to many leukemia patients and provide a useful adjunct in the detection of MRD. 
ALL epidemiology 
Acute lymphoblastic leukemia is the leading cause of cancer death in the United States among 
young people. With an incidence of 1.3 per 105 persons, it is the culprit in 23% of all childhood cancers 
and in 75% of childhood leukemias. ALL is the most common cancer in children aged 0 to 14, although 
the proportion of cases drops significantly between ages 15 and 19. According to most authors, peak 
incidence occurs between ages 2 and 3. However, there is a second smaller peak in incidence occurring in 
the seventh decade of life.1'2 These statistics have changed somewhat with time, from an incidence of 27.2 
cases per million in 1975-1979 to 34.5 cases per million in 1995-1997. The greatest proportion of this 
increase occurred between 1975 and 1984, although the reason for this is not well understood.2 
In terms of demographic factors, ALL has an increased incidence among male rather than female 
children, with the greatest difference apparent during the pubertal period. Race also appears to play a role, 
with nearly twice the rate of ALL among white children when compared to the African American 
population.26 The absolute difference in incidence between African American and Caucasian children is 
15.2 vs. 27.8 per million, and this asymmetry appears to be due mainly to a 2.4-fold increased rate of ALL 
in white children between ages 0 and 4.2 Nationality also appears to correlate with ALL incidence 
independent of race, with developing countries exhibiting lower rates of ALL when compared with 
developed nations. Interestingly, most developing nations that have been studied demonstrate an incidence 
similar to that of the United States in the mid- to late-1970’s.2' Again, the cause of this incidence shift is 





Acute lymphoblastic leukemia is believed to arise in the setting of malignant transformation of a 
single lymphoid progenitor. As is the case with most malignant neoplasia, it is likely that transition to 
uncontrolled growth begins with multiple sequential genetic changes. Spontaneous mutations or 
leukemogenic translocations conspire to dysregulate the cell cycle, leading to unlimited expansion 
capability and the capacity for indefinite self-renewal.28'30 The events associated with mutation and clonal 
expansion can precede the onset of clinical disease by years, and in the case of infantile ALL, it has been 
shown that leukemogenesis may even have its origins in-utero.31 
Leukemic blasts in ALL usually show fidelity to one hematopoietic lineage by phenotypic 
classification. However, the extent of maturation within this lineage may vary widely, which suggests that 
leukemogenic transformation results from aberrant regulation of the normal marrow differentiation process. 
This can explain the heterogeneity of the disease, as it may arise during any point along the pathway of 
lymphoid differentiation. Once induced into malignant transformation, leukemic blasts become locked into 
their discreet stage of development. At this point, the proliferating progenitor serves as a template for 
clonal expansion. Indeed, it has been shown that ALL is a clonal process, as evidenced by the consistency 
of chromosomal translocations and immunophenotype across blasts within a given patient. However, the 
best evidence for ALL clonality has been divined through X-chromosome inactivation studies, which have 
shown consistently that blasts within a given clone maintain the same pattern of X-inactivation.j2 
Somatic mutations of the lymphoid progenitor can lead to expansion and longevity by several 
mechanisms, including increased proliferative rate, decreased apoptosis, or the expression of telomerase.JJ 
These mutations may arise de novo in any child, but they are seen at higher rates in some populations. 
Notably, children with constitutional chromosomal abnormalities are at increased risk for ALL. For 
example, children with the characteristic trisomy 21 of Down’s Syndrome experience a 15-fold increase in 
the risk of leukemia, predominantly ALL.34 Additionally, children affected by disorders characterized by 
chromosomal fragility, such as Bloom Syndrome or Fanconi’s Anemia, are at increased risk. Even without 
identifiable constitutional anomalies or disorders, there is an elevated risk of leukemia in family members 
of leukemia patients. It was shown by several authors in the 1970’s that siblings of leukemic children are 
generally considered to have a 2- to 4-fold risk of developing leukemia in their lifetime relative to the 
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general population.35'36 However, these situations do not explain the majority of leukemia incidence. A 
more generally applicable explanation for the evolution of leukemia centers on the fact that normal 
lymphoid development is itself a high-risk endeavor. It is likely that there is an increased chance of 
spontaneous somatic mutation during the natural, and normally well-regulated, process of lymphoid gene- 
rearrangement in the bone marrow. This elevated degree of genetic shuffling, coupled with the high rate of 
lymphoid proliferation particularly in the developing marrow of young people, may set the stage for 
leukemogenic transformation. 
Approximately 80 to 85% of ALL patients have leukemic phenotypes corresponding to B-lineage 
progenitors.37-40 True B-cell ALL is rare, accounting for 2-3% of cases, but B-progenitor ALL is common 
and predominates over T-cell ALL. Occasionally, clones will demonstrate bi-phenotypic differentiation, 
with both T- and B-lineage immunophenotype, or expression of myeloid markers may be evident. Some 
patients also present with bi-clonal leukemias, wherein more than one clonal expansion has taken place. 
However, the majority of cases of ALL fall within the category of immature B-lineage disease. Within the 
B-progenitor group, different levels of maturation can be identified, leading to classification as pre-B, 
marked by expression of cytoplasmic immunoglobulin mu heavy-chains, and early pre-B, which lacks this 
expression pattern/0 Immunophenotyping can accurately delineate lymphoid from myeloid, B- from T- 
lineage, and subsequently classify maturational stage by expression patterns of CD markers. However, 
morphology is also used to classify ALL. The French-American-British (FAB) classification for B-lineage 
ALL is well established and fairly simple. There are three classes defined by this working group, 
designated as LI, L2, and L3. LI morphology represents 85% of cases; L2 composes 14% of cases and is 
more common among adult patients; and L3 is rare, making up 1% of cases and carrying the worst 
prognosis.41 This system is now used in conjunction with molecular and immunologic studies. 
Genetic anomalies associated with ALL are common and include aberrancies in both 
chromosomal number and structure. Structural gene rearrangements are quite common in ALL. 
Translocations are found in up to 75% of cases and are usually associated with activation of cellular 
oncogenes 42 Examples in B-lineage ALL include activation of myc by t(8; 14) translocations, E2A-PBX-1 
by t(l;19), E2A-HLF by t(17;19), MLL-AF4 by t(4;ll), MLL-ENL by t( 11; 19), bcr-abl by t(9;22), and 
TEL-AML1 by t(12;21)/0,43 There are many more examples in T-cell ALL. These rearrangements 
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typically dysregulate the function of a gene that is responsible for cell cycle control and lead to 
uncontrolled cellular proliferation. Deletions of tumor suppressor genes, such as p53 and pi 6 have also 
been documented in many cases of ALL. Alterations in chromosomal number are somewhat less prevalent, 
but are still fairly common with a role in between 20 and 40% of ALL cases.44-46 Aneuploidy can manifest 
as either hypo- or hyper-diploid cell populations, depending on whether or not DNA content is reduced or 
increased respectively. Hyperdiploidy is frequently due to trisomies, most often of chromosomes 4, 6, 10, 
14, 17, 18, 21, and X.2 Abnormal ploidy often has clinical and prognostic significance (see below). 
ALL diagnosis 
The clinical presentation of patients with ALL is largely determined by the degree of bone marrow 
infiltration and/or extramedullary spread of leukemic cells. !'2'j0 Unfortunately, presenting symptoms can 
be quite non-specific. Historical and physical findings that raise suspicion include pallor, fatigue, bone 
pain, petechiae or purpura, bleeding, or fever. These findings generally represent a failure of normal 
hematopoiesis, although the addition of lymphadenopathy, hepatomegally, and/or splenomegally may 
indicate extramedullary spread. Symptoms attributable to anemia (Hgb<10g/dL) are present in roughly 
80% of patients presenting with ALL, and those related to thrombocytopenia (Plt< 100,000 per uL) are seen 
in up to 75%.2 Indicators of extrameduallary spread are quite common as well, with hepatosplenomegally 
seen in roughly 65% of patients, and lymphadenopathy found in up to 50%. Less common sites of 
extramedullary disease at diagnosis include the CNS and testes, present in 5% of children and 10 to 15% of 
boys/0 
The non-specific nature of many of these findings leads to a broad differential diagnosis, including 
atypical lymphocytosis associated with infectious mononucleosis or pertussis, ITP, CMV, EBV, or other 
pediatric malignancies with potential marrow involvement, including neuroblastoma, rhabdomyosarcoma, 
retinoblastoma, and non-Hodgkin’s lymphoma. One additional, albeit less common, mimic is a left-shifted 
marrow in recovery from a previous toxic insult.4 Most patients have been sick for days to weeks at 
presentation, and onset of symptoms can be either gradual or quite rapid. 
Once suspicion has been raised through historical or physical findings, diagnostic testing is the 
next logical step. More than 90% of patients with ALL have clinically evident hematological abnormalities 
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evident at diagnosis.30,48 As mentioned above, routine complete blood count (CBC) will show a 
hemoglobin of less than lOmg/dL in roughly 80% of patients, and platelet counts below 100x10 ’ per pL are 
nearly as common. The leukocyte count is, however, less predictable. Approximately 50% of patients 
present with elevated leukocyte counts greater than 10xl0J per pL, and 20% will have severely elevated 
counts above 50x103 per pL. Still others will present with neutropenia or pancytopenia. Occasionally 
patients present in hyperleukocytosis syndrome, with counts exceeding 200x10J per pL, leading to 
circulatory impairment and a more acute and varied clinical picture that requires emergent treatment.47 A 
peripheral smear is indicated at the time of diagnosis in order to potentially identify circulating blasts in the 
leukemic patient. The vast majority of samples will exhibit identifiable lymphoblasts, but up to 10% of 
patients present with “aleukemic leukemia” and demonstrate no blasts in the peripheral circulation.47 
Bone marrow aspiration is essential for the definitive diagnosis of ALL. Greater than 5% 
lymphoblasts in the marrow is highly suggestive of ALL, but most institutions require a 20 to 25% blast 
constituency in order to confirm the diagnosis.2 In point of fact, about 75% of patients with ALL have 
greater than 50% marrow lymphoblasts at diagnosis/0 In order to further classify and specify the nature of 
the blasts, cells from the marrow aspirate may be immunophenotyped by flow cytometry and sent for 
cytogenetic analysis. 
The testing outlined above defines the principle diagnostic procedure necessary to confirm 
leukemia, and eventually the specific diagnosis of ALL. However, other testing will sometimes reveal or 
support identification of the leukemic process indirectly. Elevated serum uric acid secondary to increased 
cell turnover is sometimes noted in patients with ALL, particularly those with a very high leukemic burden. 
Serum lactate dehydrogenase (LDH) may also be elevated due either to increased cell lysis, ineffective 
hematopoiesis, or liver infiltration by leukemic cells. In addition to these abnormalities, a general 
metabolic dysregulation may occur, leading usually to either increased or decreased serum calcium levels 
and/or increased serum phosphate and potassium.2 
Those patients suffering from extramedullary disease at presentation may warrant additional 
studies, including imaging of CNS or mediastinal mass lesions or bilateral testicular wedge biopsies. In 
every patient, regardless of evidence of an extramedullary process, it is advisable to perform a lumbar 
puncture with subsequent cytologic study of the CSF. In some cases, lymphoblasts may be evident in 
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significant numbers within the CSF, indicating the need for specific CNS-focused adjunctive therapy 
during treatment. 
ALL treatment 
Over the last several decades ALL has been transformed from a nearly uniformly fatal disease to 
one with an impressively favorable prognosis. This evolution has been due in part to two developing 
strategies in oncology, namely risk-group stratification and the use of intensive multi-agent 
chemotherapeutic regimens, as well as the ALL-specific precautions of CNS-preventive therapy and 
extended maintenance protocols.2 Current therapy has four fundamental components. The first phase is 
induction, which is conducted with the goal of eliminating any evidence of leukemia by physical 
examination, laboratory values, and marrow examination. This equates to normal CBC and peripheral 
smear, lack of physical findings, and a marrow with normal cellularity and less than 5% blasts. In the 
pediatric population, remission can be induced in between 95 to 99% of patients.49’50 The numbers are less 
impressive for adults, but remission is still achievable in between 75 and 90% of cases.51 Along with this, 
CNS preventive treatment (or prophylaxis) is necessary using intrathecal chemotherapy and/or craniospinal 
irradiation. 
The ability to induce remission in such a high proportion of patients is quite impressive. 
However, it is notable that without any post-remission therapy most patients will relapse within a median 
time-frame of only 1 to 2 months.2 Without CNS preventive therapy this statistic is even worse due to CNS 
relapse. If disease recurrence is to be prevented, post-induction treatment must be instituted. The principle 
behind such therapy is to suppress further proliferation of the leukemic clone, to further reduce the 
circulating level of blasts, and to do so without allowing the evolution of drug-resistance. The first step 
towards these goals consists of consolidation therapy, which is an intensified treatment period following 
induction that is especially useful for high-risk patients. Consolidation serves as a “second hit” to the 
leukemic cell population after it has already been severely weakened. Even with the second hit, leukemic 
cells have shown to be resilient, and thus a prolonged period of maintenance therapy, up to 3 years in the 
case of ALL, has proven to be warranted.52 The less intensive maintenance period subsequently functions 
in long-term suppression of the leukemic clone, either eliminating it completely, or more realistically 
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subduing it to the extent that it becomes inactive or is able to be managed by host immune responses.49 
Finally, supportive care throughout the treatment process is essential, including the use of blood 
components, treatment of infection, attention to metabolic and nutritional issues, and psychosocial support. 
ALL relapse 
In spite of the advances in treatment and the increased success of ALL chemotherapeutics, up to 
30% of children, and a significantly greater number of adults, will relapse.8,12 The marrow space is the 
most common site of relapse and defines the principal form of treatment failure in ALL.2 Testicular relapse 
is less frequent, and rates have declined from 10 to 15% in the 1970’s to close to 2 to 5% currently.34,53-55 
Rates of CNS relapse have declined with effective prophylaxis, but this site remains a significant cause of 
treatment failure at just under 10%.56-57 
With a new round of chemotherapy, reinduction rates of up to 90% have been achieved for those 
with marrow relapse.38-59 The highest success rates are attained using new agents or combinations novel to 
the patient such that any drug-resistance can be overwhelmed. Other factors at play possess some 
prognostic value. A low WBC count at initial diagnosis or relapse and age between 2 and 10 years at 
diagnosis are features that predict successful reinduction.60 Additionally, the length of the first relapse is 
correlated directly with the duration of the second remission.61 However, with or without good prognostic 
features, the rate of reinduction unfortunately declines with each successive relapse.2 At this stage the 
possible need for bone marrow transplantation becomes more salient, although its success is limited in this 
setting, and it can be logistically quite challenging. 
ALL mortality and prognosis 
Prior to the formulation of modern chemotherapeutic regimens, ALL was considered nearly 
incurable, with most patients surviving only 2 to 3 months from diagnosis.30 In the 1960’s, the 5 year 
survival rate for children aged 0 to 14 was essentially zero. However, by the late 1980’s to mid 1990’s the 
5 year survival jumped to more than 80%. As mentioned above, it is thought that these improvements 
derived mainly from the implementation of risk-stratification and appropriately tailored multi-agent 
chemotherapy coupled with CNS prophylaxis and an extended maintenance period. Unfortunately, adult 
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ALL patients have not fared as well. In spite of a relatively high rate of remission induction, 5 year 
survival estimates for adults range from only 20 to 35%.j0 
There are multiple prognostic factors in ALL. Traditionally, the two most reliable and well- 
established criteria have been age and WBC count at diagnosis.62 Patients less than 2 or older than 10 years 
of age have a poor prognosis relative to the interim years. The worst prognosis within this group is for 
infants less than one year of age, whose disease tends to be quite relentless.63"64 Adults also do not fare 
well. The degree of initial leukocytosis has been cited by some as the single most important prognostic 
factor in ALL. There appears to be a linear relationship between WBC count and outcome in some studies, 
and with a count above 50x10J per pL patients have a particularly poor prognosis.65'66 
Other factors also appear to influence outcome. Boys have a worse prognosis in general than girls. 
In terms of race, African American children have a somewhat worse outcome than white and Hispanic 
children, who have roughly equivalent outcomes.67 Additional factors, more biologic than epidemiologic, 
have been brought to light as genetic and molecular tests have evolved. There is an inverse correlation 
between prognosis and lymphoblast proliferation rate as measured by cytokinetic studies, and it is surmised 
that these kinetic factors may underlie clinical responsiveness.30,68"69 Chromosomal abnormalities also 
carry prognostic significance in ALL. Translocations frequently underlie leukemogenesis. Many specific 
translocations have been identified, but some have been associated with outcome in a significant way. In 
particular, t(8; 14), t(9;22), t(4;l 1), and t( 1; 19) predispose to early treatment failure, while t( 12,21) imparts 
the chance of an improved outcome.2 Aberrations in chromosomal numeracy also affect outcome. The 
clearest example of this is the association between hyperdiploidy, with a DNA index greater than 1.16, and 
improved prognosis.20"21,44 Several reports have actually shown lymphoblast ploidy to be the most 
significant prognostic factor in childhood B-progenitor ALL.45"46 It is thought that the benefits of 
hyperdiploidy may be related to increased leukemic sensitivity to antimetabolite chemotherapeutic 
agents.70"71 Patients with Trisomies 4 and 10 also have an improved outcome.72 Hypodiploidy, on the other 
hand, is a negative prognostic factor, with the worst outcome reserved for those with near-haploid 
genotypes.22"24,73 
Immunophenotypic factors include lineage and maturation, with T-cell and mature B-cell ALL 
carrying worse prognoses than precursor-B-cell ALL. A somewhat more controversial idea is that aberrant 
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expression of myeloid markers may be associated with poor outcome. Finally, L3 morphology has been 
shown to be associated with a worse prognosis than either the LI or L2 subtypes.’0 Of greatest interest to 
the topic of this report, minimal residual disease (MRD) has emerged in recent years as a major prognostic 
issue, and this will be visited in depth in the following section. 
MRD background 
Traditionally it was assumed that curing ALL was synonymous with elimination of all leukemic 
cells.2 However, as sensitive means of detecting small numbers of cells in marrow samples have evolved, 
so has the realization that leukemic cells can remain in their host even after successful chemotherapeutic 
interventions. According to current standards, ALL is considered to be in remission when the blast 
population falls below the limit of morphological detection and constitutes less than 5% of non-erythroid 
marrow cellularity.15,74-75 However, with a relatively standard leukemic burden of 1012 neoplastic cells at 
diagnosis, a patient in remission may continue to carry up to 1010 cancer cells.12 20 Thus, a very successful 
several log reduction in leukemic burden may leave behind billions of clonal cells which may or may not at 
some stage repopulate the marrow in the form of relapsed disease. Although some have questioned 
whether or not these “remaining” cells constitute the vestige of a pre-leukemic clone or whether they 
indeed represent the original clone at diagnosis, it is fairly clear that the presence of minimal residual 
disease (MRD) may imply the presence of a leukemic stem cell capable of inciting recurrent disease.17,49 
Detecting post-therapy residual disease began with simple morphologic examination of the bone 
marrow for visible blasts, allowing for a discriminatory sensitivity down to 5% neoplastic cells. This was 
later supported with the use of fluorescence microscopy and labeled polyclonal antibodies, initially limited 
to the study of T-cell ALL. With the advent of monoclonal antibodies and the isolation of B-lineage 
surface markers, this technology became more widely applicable to the majority of ALL cases. However, 
these techniques had limited sensitivity because they involved analysis of only small samples of marrow. 
A similar lack of sensitivity hinders fluorescence in-situ hybridization (FISH) studies and traditional 
karyotyping. The development of flow cytometry and its application to analysis of large numbers of cells 
in hematological malignancies allowed sensitivity to be increased significantly. In addition, PCR 
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technology became available in the 1980’s and was applied to the problem.76 These most recent methods 
provide greatly increased sensitivity for MRD detection. 
MRD methods of detection 
There are several requisites for creating a reliable and accurate assay for the detection of MRD. 
First, specificity is necessary in order to discriminate between normal and neoplastic cells. Second, 
sensitivity is needed to detect a relatively small number of neoplastic cells against a background of normal 
marrow constituents. Third, the assay must be standardized and reproducible. And, fourth, turnaround 
time from aspirate or biopsy to diagnostic report must be rapid enough to be clinically useful.8 
However, difficulties exist in determining whether or not a patient with ALL is in “complete 
remission”. First, there is massive sampling error attributable to the bone marrow biopsy or aspiration 
procedure. The percentage of marrow taken for examination is miniscule, and in the post-therapeutic 
marrow the number of blasts is greatly reduced. In addition, malignant cells may not be uniformly 
distributed within the medullary space. Secondly, the morphologic identification of MRD is of limited 
sensitivity. The lowest documented limit of detection by experienced cytologists was shown to be roughly 
1%, and a limit of 5% is the more generally accepted number.8,17 This is further compromised in the post- 
therapeutic marrow due to the presence of an increased number of normal hematopoietic precursors, or 
hematogones, that can be present at proportions greater than 5% and which can be quite easily mislabeled 
as blasts.18'19 It has, unfortunately, been estimated that the amount of MRD detectable by microscopic 
morphology is 300-fold that required to cause relapse, and rough quantitation reveals that 
cytomorphological techniques may only be able to identity fewer than 30% of ALL patients who are 
destined to relapse.8'9 Although occasionally useful for closer examination of morphologically suspicious 
cells, the additional methods of conventional karyotyping and FISH are also limited in sensitivity and 
cannot reliably detect sub-microscopic disease below 1 to 5%.17 
The most widely accepted high-sensitivity methods in use today are flow cytometric 
immunophenotyping and polymerase chain reaction (PCR) gene amplification. Both of these methods, 
when applied meticulously, can achieve a level of sensitivity more than 100-fold greater than that provided 
by standard morphologic studies.9,13'14,17 With this level of detection, submicroscopic residual disease can 
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be identified, and a more strict definition of remission may be cultivated. PCR technology involves the use 
of sequence-specific primers under changing temperature conditions in order to replicate DNA or mRNA 
sequences present in a sample. These sequences are amplified in logrhythmic fashion until the product is 
detectable on gel electrophoresis, whereupon its presence can be confirmed by both its position within the 
gel field and with radio-labeled probes to the sequence of interest.16 Flow cytometric immunophenotyping 
utilizes analysis of light emission and scatter from monoclonal antibody-bound fluorochromes that attach to 
specific cell surface or intracytoplasmic markers. Data derived from this process allows demarcation of 
different cell populations by immunophenotype. Both of these processes can be directed towards the rather 
sensitive detection of leukemia-specific targets and therefore allow detection of MRD. 
MRD methods of detection: PCR 
There are two discreet classes of target for PCR amplification in the detection of MRD in ALL. 
One set of targets consists of the breakpoint fusion regions of chromosomal translocations. Because of the 
fact that breakpoint fusion regions associated with most known leukemic translocations are spread over 
large expanses within each gene locus, reverse transcription PCR (RT-PCR) of mRNA transcripts of these 
regions is more widely applicable than standard PCR. Being that the sequences of these transcripts are 
relatively stable across most patients who possess the same translocation, it is relatively simple to amplify 
and detect these targets without the need for customization for each patient.77 The second set of targets for 
PCR are the functional regions of rearranged immunoglobulin heavy chain (Igh) or T-cell receptor (TCR) 
genes.17 These rearrangements are unique to a given leukemic clone and will be present in every leukemic 
cell derived from it. 
It has been found that MRD detection is highly concordant between these two types of targets.10 
However, each has significant positive and negative attributes. RT-PCR of fusion transcripts has the 
advantage of high sensitivity and relative rapidity of processing. In addition, translocations almost 
invariably remain stable through the course of the disease and are not easily influenced by clonal evolution. 
The ability to use prefabricated primers once a given translocation has been identified provides both 
resource and time savings for the diagnostic department involved. Perhaps the biggest drawback to using 
fusion transcripts is that specific chromosomal changes associated with well-defined breakpoint fusion 
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regions are present in less than 50% of ALL cases.78'79 This imposes a serious restriction on the 
widespread use of such techniques, with applicability to roughly 40-50% of patients. Additionally, it can 
be difficult, or at least theoretically ambiguous, to quantify MRD using RT-PCR, as there may be variable 
expression of any given mRNA transcript depending on proximity to treatment, leukemic cell death, and 
other unpredictable parameters.79 Beyond this, false negative results can arise due to mRNA degradation, 
and false positive results can arise in the setting of RNA cross-contamination.17 Standard PCR of Igh and 
TCR rearrangements also has the benefit of high sensitivity, but can deliver extremely wide applicability 
due to the fact that virtually all ALL clones have a characteristic gene rearrangement. Applicability of this 
technique approaches 90% of ALL patients. In addition, quantitation of MRD can be achieved using these 
targets. The focus for this technique is amplification of DNA rather than mRNA transcripts; therefore there 
are a fixed number of targets to be amplified in each cell which do not vary with altered expression 
patterns.17 The amplification product is truly based on the number of clonal cells present rather than on the 
genes they may or may not be expressing. Because Igh and TCR gene rearrangements are unique to each 
clone and therefore to each patient as well, a major drawback is the requirement that rearranged gene 
sequences must be identified at diagnosis in every ALL patient. After identification and sequencing, 
patient-specific junction-region-specific oligonucleotide primers must be manufactured. This process adds 
significant cost and time constraints. In spite of all of this, false negative results can arise due to clonal 
evolution or the appearance of sub-clones not evident at diagnosis, both of which decrease or eliminate the 
utility of the primers customized to the original leukemic genotype.1' 
Regardless of what target is used, PCR techniques are capable of sensitivities ranging from 
detection of one leukemic cell in 10J to 10° normal background cells. Quantitation is difficult with fusion 
transcripts, but it is quite accurate using gene rearrangements, and the advent of real-time quantitative PCR 
technologies may expedite and further tailor the method of MRD quantitation. In general, it must also be 
noted that even PCR-negative patients may harbor between 104 and 105 leukemic cells considering the 
increased but still finite sensitivity of the technique, and so a negative PCR result should not be interpreted 
as the complete absence of leukemic cells. In addition, PCR-positive patients may be identified as 
leukemia-free if the most stringent cleanliness and procedural standardization has not been followed. In 
terms of sampling error, not only is marrow aspiration or biopsy limited, but it is reasonable to assume that 
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MRD levels can fluctuate both above and below the limits of PCR detection, thus leading to a temporal 
variability that could produce false-negative results.80 The theoretical question of whether or not there ever 
can be elimination of all leukemic cells, and whether or not this matters clinically, soon becomes apparent. 
Is there a finite limit to sensitivity? Can any chemotherapy regimen ever kill every malignant cell? Will it 
eventually have to in order to meet a future standard of care? Most likely there is a degree of elimination at 
which remaining leukemic cells either lose their ability to get an “exponential head start” or the host 
immune system is able to chronically suppress any further clonal expansion.49 
MRD methods of detection: flow cytometric immunophenotyping 
Targets for flow cytometric detection of MRD rely on leukemia-associated immunophenotypes 
associated with the patient’s malignant cells. Essentially, a pattern of surface marker expression unique to 
the clone and not expressed by normal marrow or blood constituents is sought at the time of diagnosis by 
flow cytometry of cells derived from the marrow aspirate. This proves relatively straightforward for T- 
lineage ALL, by virtue of the presence T-cells outside of the thymus with a ubiquitous leukemia-associated 
immunophenotype in the form of CD3 or CD5 and TdT positivity.20 76’81 However, isolation of aberrant 
expression patterns can be more complicated for B-lineage ALL, especially when the malignant cells have 
been derailed early in the differentiation process. Once a distinguishing immunophenotype has been 
identified, post-remission marrow samples can be assayed with high sensitivity in order to detect residual 
leukemic cells expressing the same clonal pattern of surface markers. 
As stated above, it can be difficult to distinguish the immunophenotypic characteristics of B- 
lineage ALL cells from those of normal early lymphoid progenitors, also known as hematogones. Current 
understanding of leukemogenesis is founded on the principle that leukemia originates from the clonal 
expansion of a transformed hematopoietic cell that has been arrested at a particular stage of differentiation. 
The implication of this is that B-lineage leukemic blasts are directly related to their normal counterparts in 
lymphopoiesis. It has been documented that normal cells with aberrant immunophenotypes, such as co¬ 
expression of T-cell or myeloid markers and simultaneous expression of both early and late differentiation 
antigens, can be found in normal bone marrow at the 1 in 104 sensitivity level.18,82 Just as with 
morphologic screening, these relatively immature cells can also be immunophenotypically confused with 
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leukemic blasts during flow cytometric assays. And, the issues is made more complicated by the fact that 
numbers of these progenitor cells can escalate significantly in regenerating marrow following 
chemotherapy or bone marrow transplant. Beyond this, hematogones are present in higher proportions in 
the marrow of young children at baseline, and this population bears the burden of most ALL cases.83’84 
Some recent work has suggested that leukemic cells can be distinguished from normal B-ceil 
precursors by quantitative expression levels of certain antigens using so-called comparative phenotype 
mapping.18,85'86 Other authors have reported methods using non-quantitative expression patterns. One 
report found increased expression of markers such as CD-58, creatine kinase-B, ninjurin-1, REF1, 
calpastatin, HDJ-2, and annexin-VI in B-lineage ALL cells when compared to B-cell precursors, and CD- 
58 staining correlated well with PCR of Igh gene rearrangements.76 Another report found that simultaneous 
expression of CD-19, CD-10, and either CD-34 or TdT exhibited some sensitivity. This author suggested 
that quantitative differences in antigen expression could be used in between 30-50% of cases to distinguish 
normal and leukemic cells, and that with larger panels of markers this might be raised to roughly 85%.20 
Weir et al.19 used a four-color flow cytometry apparatus to distinguish up to 99% of hematogones from B- 
precursor ALL cells in a sample of 82 cases. Another author has suggested that leukemia-associated 
immunophenotypes (LAIP) can be identified in up to 90% of B-lineage ALL.87 Regardless of the progress 
being made in identification, the issue of immunophenotypic overlap between ALL cells and marrow 
precursors remains influential in daily practice. In recent years it has been estimated that approximately 2/3 
of pediatric ALL patients can be monitored for MRD with any prognostic relevance when using standard 
immunophenotyping techniques.74,88 Even this generous estimate leaves roughly 30% of ALL patients with 
a diagnostic dilemma regarding MRD detection. A highly sensitive technique can make for ambiguous 
results when specificity is lost. 
Flow cytometric immunophenotyping is an efficient technique in that it is particularly rapid. It is 
fundamentally an excellent method for quantification of disease, as its historical roots were based in cell 
counting. Additionally, it provides a broad overview of hematopoietic status as part of routine processing. 
One additional feature that distinguishes its utility from that of PCR is the ability to distinguish viable from 
apoptotic cells within a given sample. Difficulties with flow IP include false-negative results due to 
immunophenotypic shifts in the leukemic clone, although the confounding effects of this issue can be 
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reduced by the use of multiple markers, when available. A more significant lineage switch, with ALL 
relapsing as AML, or a secondary hematological malignancy due to the mutagenic effects of chemotherapy 
may also occur.1,20 False-positive results arise mainly through the inappropriate choice of markers to 
delineate normal from malignant cells due to human error. Finally, there is significant complexity involved 
in the interpretation of immunophenotype data once it has been gathered and analyzed, which is both time 
and labor consuming, as well as providing fodder for misinterpretation.17 
Two general variables influence the effectiveness of MRD detection by flow cytometric methods. 
The first, as outlined above, is the degree of morphologic or immunophenotypic difference between 
malignant and normal background cells. The second is the quantity of cells that can be analyzed. Flow 
allows for a sensitivity of up to 1 in 106 cells if a sufficient number of cells are analyzed (the magic number 
being roughly 107 total cells) and if the fluidics system of the cytometer is painstakingly maintained. 
However, more realistic sensitivity estimates for clinical (non-research) machines hover around 1 in 104 to 
105 cells.20 In everyday practice, with approximately 106 cells to assay, and considering the need for at 
least 10 to 20 data points for adequate interpretation, a sensitivity of 0.001% (1 in 10? cells) should be 
achievable.76 
MRD prognostic significance 
It has been repeatedly documented in recent years that MRD has prognostic significance for 
patients with ALL (see below). The presence and quantitative level of residual leukemic cells at multiple 
time-points predicts likelihood of relapse and event-free survival with great power, and the predictive value 
remains robust even when adjusting for other prognostic factors. The following paragraphs offer a review 
of multiple studies conducted regarding the prognostic value of MRD detection using either PCR or flow 
cytometric technology. 
MRD prognostic significance: PCR 
PCR-based MRD detection does possess prognostic significance in ALL. VanDongen et al.9 
conducted a prospective study of 240 childhood ALL patients being treated in Europe. Bone marrow 
samples were collected at up to 9 time intervals both during and after treatment, and PCR of patient- 
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specific lgh and TCR gene rearrangements, as well as TALI deletions when applicable, was conducted. 
All patients had appropriate targets for PCR, and 62% of patients had either 2 or 3 available targets. Of the 
36 patients that relapsed, 94% retained at least one stable PCR target. The loss of targets mainly affected 
T-lineage patients, likely due to continued clonal rearrangements. Only one B-lineage ALL patient lost 
viable targets completely. Data showed that positive MRD status during treatment led to a 5 to 10-fold 
increase in relapse rate. The difference was highlighted the most at detection time-point 5 before the end of 
treatment, with 9% of MRD-negative patients vs. 86% of MRD-positive patients from this group relapsing 
at 3 years. For those who remained MRD-positive after treatment was completed, 5 of 6 patients relapsed, 
although 9 of 148 MRD-negative patients eventually relapsed as well. Upon multivariate analysis, 
presence of MRD was found to be an independent prognostic factor at each of the first 5 time points used in 
the study. In addition, a quantitative correlation was found, with distinct degrees of MRD having specific 
prognostic significance. Each 10-fold increase in degree of MRD produced a 2-fold increase in relative 
risk of relapse. Importantly, this relationship remained significant between each treatment classification 
group (standard-, moderate-, and high-risk), and the prognostic impact was consistent even after controlling 
for age, sex, initial WBC count, and immunophenotype. This work clearly demonstrated the prognostic 
value of MRD detection in ALL, and made the important step towards association of MRD quantification 
with outcome variability. 
Cave et al.8 conducted a prospective study of 178 patients with childhood ALL, collecting bone 
marrow specimens at 4 time points during the first 6 months after remission induction. PCR amplification 
of patient-specific gene rearrangements was again employed for detection of MRD. At least one target was 
available in all patients, with 26% possessing more than one probe. Compared to the MRD-negative 
patients, those with positive MRD status before consolidation therapy had a relative risk of relapse of 4.9. 
Positive MRD status continuing after consolidation amplified the effect, with the relative risk of relapse 
jumping to 15.0. Among relapsed patients, those with detectable MRD at the completion of induction 
therapy displayed a shorter time to relapse than those without MRD. In an attempt to quantity the effect, 
patients were stratified by MRD level into groups with less than 1 leukemic cell per 10J normal marrow 
cells, between 1 per 10Jand 102, and greater than 1 per 102. As expected, the risk of relapse increased 
sequentially with level of MRD. Not surprisingly, survival was also related to presence and level of MRD; 
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those with MRD-positive status were burdened with a 10-fold greater risk of death within the studied time 
frame than those with no detectable MRD. Again, the prognostic significance of MRD remained stable in 
bivariate analyses with risk-group stratification, age, WBC count, and immunophenotype. 
Gruhn et al.12 conducted a smaller study of 26 children with B-lineage ALL in which post¬ 
induction marrow samples were analyzed for MRD. A quantitative semi-nested PCR procedure was 
utilized to amplify Igh gene rearrangements. After completing PCR studies, MRD-positive patients were 
divided into a low-level group, with less than 2 malignant cells per 103 normal marrow cells, and a high- 
level group, with greater than 2 per 105. According to the collected data, all patients with low or 
undetectable levels of MRD remained in complete remission with a median follow-up of 5.25 years, while 
all patients with higher levels subsequently relapsed. In spite of the small sample size, this author 
concluded that level of MRD following induction therapy predicts outcome in childhood B-lineage ALL. 
The suggestion was also posited that it may be advisable to utilize this factor for a new form of risk 
stratification, in which post-induction MRD-positive patients should be given more intensive therapy and 
possibly even bone marrow transplantation. It is, however, difficult to set consistent cut-off points between 
low- and high-risk patients, as these demarcations may be influenced by intensity of induction therapy, time 
of marrow examination, and even method of MRD detection. 
Another small study was conducted more recently by Gameiro et al.10 using a sample of 52 
children with ALL (44 of whom had common or pre-B ALL). PCR was attempted utilizing both antigen 
receptor gene rearrangements and fusion transcripts, when applicable. The patients involved were 
monitored for a median of 45 months, with marrow examinations within 4 time periods, 0-2 months, 3-5 
months, 6-9 months, and 10-24 months. Seventeen patients relapsed, but only 11 were able to be followed. 
Of this group, 3 had lost their original clonal PCR target, demonstrating the difficulties caused by clonal 
evolution when using PCR analysis. The remaining 8 patients retained their original PCR target(s) and 
were able to be followed. During the first 24 months, MRD detection correlated with outcome for all time 
periods, and proved to be not only independent but also more accurate in predicting outcome than age and 
WBC count. MRD-positivity was associated with an increased relative risk of relapse, with this impact 
growing stronger with time. At each time-block the relative risk of relapse for MRD-positive vs. negative 
patients was 1.89 vs. 0.72, 2.20 vs. 0.82, 2.65 vs. 0.65, and 2.16 vs. 0.70. Clearly, the greatest association 
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was observed at the 6-9 month time period, corresponding to the start of maintenance therapy. Among 
those who relapsed, at all 4 time points the number of MRD-positive patients exceeded the number of those 
with undetectable MRD. As with the aforementioned studies, 3 subgroups of MRD-positive patients were 
created including those with greater than 1 leukemic cell per 102 normal marrow cells, those with between 
1 per 103 and 1 per 104, and those with less than 1 per 104. Level of MRD-positivity was significantly 
associated with disease-free survival at all time periods. 
Eckert et al.11 conducted a retrospective study of 30 children with ALL utilizing PCR 
amplification of Igh and TCR gene rearrangements. Patients were divided into subgroups with MRD 
quantified as greater than 1 leukemic cell per 10J normal marrow cells or less than 1 per 10'. At day 36 of 
therapy, the probability of event-free survival at 6 years was 0.86 for the low-level MRD patients versus 
0% for those with higher levels of MRD. These results suggest that the extent of early response to therapy, 
as evidenced by levels of residual leukemia, can be used to predict long-term outcome in ALL patients. 
Those whose MRD levels are low at early time points may have a more brisk response to therapy, and may 
therefore have a better eventual outcome. Again, this information may be helpful for risk stratification and 
subsequent adjustment of treatment intensity to better match prognosis. 
Another smaller retrospective study conducted by Roberts et al.15 sequentially followed 24 
children during their first clinical remission from B-precursor ALL during a 5 year follow-up period. MRD 
was monitored using quantitative PCR of Igh gene rearrangements. Among the patients who relapsed, 
levels of residual leukemic cell DNA were significantly higher by quantitative PCR when adjusted for time. 
However, the mean level of leukemic cell DNA at any specific time was not associated with probability of 
relapse, suggesting the need to follow time trends. Notably, 15 of 17 patients who remained in CCR and all 
5 relapsed patients had some degree of detectable residual disease. However, the PCR results did show a 
temporal pattern of increasing MRD levels in those who relapsed. Unfortunately, no threshold level of 
residual leukemic DNA was significantly associated with relapse. However, autoregression calculations 
demonstrated significant association between a trend of increasing levels of MRD and eventual re- 
emergence of disease. Thus, a predictive value before relapse was found. The fact that so many patients in 
CCR remained MRD-positive at some level further challenges the dogma of equating cure with complete 
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elimination of leukemic cells. With higher sensitivity methods comes the detection of more minute levels 
of disease that may, at some threshold, lose clinical significance. 
Goulden et al.16 studied 66 children with ALL retrospectively, but added the additional control of 
limiting the study set to those with only standard-risk ALL. Again, PCR amplification of Igh and TCR 
gene-rearrangements was performed. Bone marrow aspirates were collected at 1,3, and 5 months into 
treatment, and the presence or absence of MRD was documented for both those in CCR and those who 
relapsed. At these sequential time intervals for patients in CCR vs. those who relapsed, MRD-positivity 
was present in 32% vs. 82%, 10% vs. 60%, and 0% vs. 41% respectively. It is clear that MRD was more 
prevalent among those who relapsed, and that a downward trend with time led to eventual MRD-negativity 
for those in CCR. In these standard-risk patients without additional adverse prognostic factors MRD- 
positivity was still significantly associated with relapse. 
A retrospective analysis of 90 ALL patients, 19% of whom possessed the TEL/AML 1 
translocation, was performed by DeHaas et al.89 The aim was to determine whether or not the presence of 
MRD retained its prognostic value even with the presence of a beneficial prognostic factor such as the 
TEL/AML1 rearrangement. PCR was performed using antigen receptor gene rearrangements as per usual, 
and levels of MRD were measured after induction therapy. Patients who went on to relapse had 
significantly higher levels of MRD when compared with those who achieved CCR, and indeed this same 
pattern held true for the patients with the TEL/AML 1 translocation. This study serves as one example of 
the persistence of MRD as a prognostic factor despite the presence of other prognostic variables. 
MRD prognostic significance: flow cytometric immunophenotyping 
The prognostic value of flow cytometric detection of MRD has also been demonstrated in the 
literature. Dworzak et al.14 conducted a prospective study of 108 children with ALL using flow cytometric 
assessment of bone marrow samples at 4 time periods during the first 6 months of treatment. MRD was 
quantitatively assessed based on both the number of blasts relative to normal nucleated marrow cells and by 
absolute measures of leukemic cells per microliter. At all time points except day 15, the presence of MRD 
was associated with greater likelihood of relapse. In fact, 99% of assays using day 33 marrow had 
sufficient sensitivity for outcome prediction. Importantly, incidence of relapse was found to correlate with 
. 
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distinct levels of MRD-positivity. The author found a high predictive value in combining MRD data from 
day 33 and from week 12. The earlier data provided a sensitive pre-definition of high-risk patients, while 
the later data allowed for estimation of the kinetics of MRD evolution between two time points. Overall, 
MRD measures by flow cytometry proved to be an independent, and even overriding, prognostic factor in 
multivariate analyses using other risk factors, including the Berlin-Frankfurt-Munster (BFM) risk 
stratification scheme. Based on these results, the author suggests a new multilayered risk stratification 
system, placing patients at high conventional risk (HR) into an MRD-positive group, with particularly bad 
outcome and the need for alternative therapies, and an MRD-negative group with a relatively good 
prognosis using intensive chemotherapy. A second set of patients would be those with low conventional 
risk (SR or MR), who could be divided into an MRD-positive group, with an increased chance of relapse 
and the need for therapy intensification, and an MRD-negative group who would have an excellent 
outcome with standard chemotherapy protocols. The author raises an interesting point in that the predictive 
value of MRD detection may vary with the intensity and schedule of chemotherapy. This type of variable 
warrants further investigation. Also of interest, this study substantiated the previously documented 
difficulties reported by many authors regarding the inability to distinguish lymphoid precursors from B- 
lineage leukemic blasts by immunophenotyping. 
Another prospective study was conducted by Coustan-Smith et al.6 involving 195 childhood ALL 
patients in newly diagnosed remission. Bone marrow samples were collected at the end of remission 
induction and at 3 later time points and then subjected to immunophenotypic analysis by flow cytometry. 
At all measured points during clinical remission, the presence of detectable MRD was associated with a 
higher rate of subsequent relapse. In particular, patients with high levels of MRD at the end of induction or 
at week 14 of continuation therapy had an especially poor outcome. Among patients who were MRD- 
positive at the end of induction, those who remained MRD-positive through week 14 of continuation 
therapy relapsed at a rate of 68%, whereas those who became MRD-negative by week 14 of continuation 
had a relapse rate of only 7%. As noted in other studies, the predictive strength of MRD detection 
remained significant even after adjustment for other prognostic factors. Some presenting features, such as 
the patient’s age and presence of certain genetic anomalies, are related to the rate and extent of initial 
cytoreduction, but notably, MRD detection at the end of induction therapy continued to identify patients at 
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higher risk for relapse regardless of rapid clearance of leukemic blasts. In spite of fairly compelling results, 
this author suggested the use of tandem flow cytometry and PCR analysis in order to eliminate the risk of 
false-negative findings due to immunophenotypic shifts or clonal evolution.6,90 Overall, however, the 
results clearly demonstrate prognostic utility for the flow-based measurement of MRD. 
Another study by the same author involved prospective analysis of 158 children with ALL using 
flow cytometry to identify and follow leukemia-associated immunophenotypes.74 Marrow samples were 
collected at the end of induction, as well as at weeks 14, 32, and 56 of continuation, and at week 120 (the 
end of therapy). At each time point analyzed, detection of MRD was significantly associated with a greater 
likelihood of treatment failure and disease relapse. The predictive value of MRD remained robust after 
adjustment for age, WBC count, and presence of the Philadelphia chromosome or MLL gene 
rearrangement. The overall conclusion was that immunological detection of MRD by flow cytometry at 
any point during the course of treatment is a powerful predictor of relapse in children with ALL. 
Just prior to Coustan-Smith’s 1998 report, Farahat et al.75 published a paper detailing a 
retrospective study of 53 children with B-lineage ALL. Patients were monitored for MRD with the use of 
flow cytometry to detect CD10+, CD19+, TdT+ cells in the marrow at several points during therapy. MRD 
was detected despite negative morphology in many cases, leading the authors to conclude that quantitative 
flow cytometry was a superior technique for assessment of remission status. There was a statistically 
significant difference in disease-free survival rates between MRD-positive and MRD-negative patients at 
the start of morphological remission. Presence of MRD reliably predicted early relapse, and thus a 
correlation between MRD status and outcome was confirmed. 
Borowitz et al.lj attempted to correlate MRD with other risk factors in 1016 children with 
precursor-B-cell ALL. The authors utilized 4-color flow cytometry to analyze marrow samples at the end 
of induction therapy, while simultaneously screening for other risk factors in ALL such as clinical risk 
stratification, cytokinetic responsiveness, and genetic abnormalities within the leukemic clone. MRD 
levels correlated with NCI risk-group stratification, showing that NCI high-risk patients were more likely to 
be MRD-positive than the standard-risk group. This suggests that poor clearance of leukemic cells during 
early therapy may partially explain traditional high-risk characteristics. Along these same lines, patients 
demonstrating a slow early response to chemotherapy as judged by day 8 marrow morphology were more 

24 
likely to be MRD-positive at the end of induction. Interestingly, flow cytometry of day 8 blood samples 
and morphologic examination of day 8 marrow proved to be independent predictors of later MRD- 
positivity. The authors suggest that monitoring of day 8 blood by flow methods may identify which 
patients might benefit from marrow examination, thus saving some patients from unnecessary aspirations 
and ensuring adequate surveillance for those at higher risk. Genetic factors were also assessed in this 
report. It was found that Philadelphia chromosome-positive patients tended to have higher levels of MRD. 
Those with the favorable TEL/AML 1 translocation were found to have relatively low rates of MRD- 
positivity, consistent with other reports that patients with this anomaly tend to be rapid responders to 
conventional chemotherapy.91 Interestingly, patients with the favorable trisomies 4 and 10 were found to 
have a 2- to 3-fold higher incidence of MRD-positivity when compared with standard ALL patients. 
Further work must be done to determine if MRD-positive trisomy-positive children have higher relapse 
rates. However, with the typically beneficial nature of trisomies 4 and 10, early intensification of treatment 
for MRD-positive patients would likely be overzealous. This curious development lends caution to 
assumptions that MRD status may trump all other prognostic factors. 
In an attempt to confirm the significance of MRD detection among other age groups, Vidriales et 
al.92 studied 102 adolescent (age greater than 14) and adult patients with ALL using flow cytometric 
immunophenotyping of day 35 marrow samples. Multivariate analysis showed that immunologic 
evaluation of day 35 marrows was actually the most robust independent prognostic factor for these patients. 
The authors concluded that, in combination with age, WBC count at diagnosis, and presence of genetic 
anomalies, MRD detection allowed for very informative prediction of relapse-free survival. This serves as 
evidence that flow cytometric MRD studies have broad applicability to ALL patients, regardless of age- 
group. 
MRD and DNA ploidy 
It has been shown that results and sensitivities of MRD detection correlate well between PCR and 
flow cytometric immunophenotyping.90 There are advantages and disadvantages to both, and in time 
perhaps all samples will be subjected to both modalities, as has been suggested by some.6,90 However, 
many institutions, including our own, rely on flow cytometry technology for MRD detection. In spite of 
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the success in measurement of MRD by flow cytometric methods and its clear prognostic value, the 
previously mentioned difficulties due to proliferation of B-cell precursors in therapeutic bone marrow 
remain a challenge in a substantial number of ALL cases. In order to clarity this area of blurred specificity, 
particularly in the realm of B-lineage ALL, it is necessary to find additional distinguishing characteristics 
of residual leukemic cells that do not rely on overlapping immunophenotype. With up to 40% of B-lineage 
ALL cases demonstrating aneuploidy, the presence of abnormal DNA content may be a variable that can be 
used in at least a proportion of cases to assist in the accurate detection of MRD. DNA ploidy analysis can 
be conducted using a flow cytometer, and has been used for quite some time to characterize both solid and 
hematological tumors. The tandem use of flow cytometric immunophenotyping and DNA ploidy analysis 
in B-lineage ALL is a logical combination, as both assays can be conducted rapidly with the same 
apparatus, and both sets of data can be interpreted together. 
History of flow cytometry 
Since the 1930’s, when the evolution of flow cytometry began, the technique has been developed 
and refined to allow researchers and clinicians to analyze great numbers of cells rapidly and accurately.93"94 
With the invention of the microscope in the 1600’s, the development of better tissue stains in the late 
1800’s, and eventually the discovery of fluorescent markers and photodetectors to measure their output, 
cytometry has developed, first from direct observation of cells, to rapid analysis using computer 
technology. The first steps towards a “flowing” system, in which cells are analyzed as they move in a fluid 
stream, began in 1930’s with Andrew Moldavan’s invention of a device to count erythrocytes and Torbjom 
Caspersson’s progressive use of microspectrophotometers to measure the UV absorption of cell nuclei.93,95 
This gave way in the 1950’s to the familiar Coulter technology that has allowed rapid counting of cells in a 
liquid stream based on impedance characteristics. 
In the 1960’s this technology was adapted by Louis Kamentsky with the addition of a microscope- 
based spectrophotometer which was calibrated to measure UV absorption and the scatter of blue light from 
cell flowing past an objective. Further along in the decade, Dittrich & Gohde furthered the process by 
creating a device that could measure ethidium bromide-stained nuclear DNA fluorescence and create 
intensity-derived histograms of DNA content. This procedure serves as a foundation for the current DNA 
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ploidy analysis that has been mentioned above. From here, the goal shifted to cell sorting, and in the late 
1960’s newly emerging ink-jet technology was harnessed in conjunction with Coulter technology by Mack 
Fulwyler at the Los Alamos Laboratories to create an instrument capable of sorting erythrocytes. All of 
these developments led to creation of the first fluorescence detection cytometer in 1969 by Marvin Van 
Dilla, also at Los Alamos Laboratories. By 1970, separation of leukocytes began to be achieved, and from 
there the technique grew.95 With time, the analytical speed of current machines has exceeded that of the 
early slide-based microspectrophotometers by 4 to 5 orders of magnitude.96 
Development of fluorochromes and monoclonal antibody technology has led to the use of flow 
cytometry for research and clinical purposes, but perhaps its most powerful use has been in the field of 
hematopathology. Here three-color, and now four-color, flow cytometry using fluorochromes attached to a 
wide variety of monoclonal antibodies against leukocyte CD markers has allowed for precise identification 
of leukemic cells and delineation of maturational status. 
Flow cytometry principles 
Flow cytometry has applications in both solid and hematological tumors. In either case, the utility 
of the technique lies in rapid analysis of a large number of cells flowing single-file in a fluid stream 
exposed to high-intensity laser light.94 
The basis for immunophenotyping in ALL traces back to the mid 1970’s, when flow technology 
was used at the ICRF Tumor Immunological Unit in London to test an antiserum which reacted with a 
leukocyte surface antigen termed CALLA (for common ALL antigen), now known as CD-10.97 Evolution 
of monoclonal antibody technology and a series of leukocyte-typing workshops led to delineation of an 
extensive list of CD markers. Multiparameter flow cytometry was then poised to trace the steps of 
maturation among the lymphoid cell lineage. In this way, normal B-lymphoid development was worked 
out, and the highly controlled sequential acquisition of leukocyte surface markers was outlined. At the 
same time, it became clear that while normal differentiating cells express surface antigens in an orderly and 
predictable fashion, leukemic cells follow a dysregulated and confused pathway.97 From here, the clinical 
use of flow immunophenotyping became clear, as it promised a more objective criterion to support the 
morphological diagnosis and classification of ALL.98 B-lineage precursors commit to their pathway with 
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the expression of surface CD 10, CD 19, and CD22, nuclear TdT, and cytoplasmic CD79a. As they 
progress, these early B-cells sequentially begin to lose CD34 and nuclear TdT, express decreasing amounts 
of CD 10, and gain reactivity for CD20. Later, cytoplasmic immunoglobulin mu heavy chains are 
produced, until eventually light chains are made and complete secretory and surface immunoglobulin 
molecules can be identified. Aberrancy during this process, either through cross-lineage expression 
patterns or asynchronous antigen expression, can identify neoplastic cells.98 Analysis of extracellular 
targets, such as leukocyte surface antigens, involves incubation of blood or marrow with fluorochrome- 
labeled monoclonal antibodies to specific surface markers. By this process, the presence or absence of 
markers can be determined based on positive or negative fluorescent staining. Cells exposed to antibody 
are passed single-file through a focused light source, typically an argon laser. Interaction of fluorochrome 
molecules with laser light allows for excitation of electrons. After excitation, the subsequent orbital energy 
changes associated with electron transit back to resting state produce emitted light, and the cells themselves 
produce scatter of the laser photons. At this point, light is separated by wavelength using a series of 
mirrors and filters and directed towards fluorescence photodetectors, which allow for a quantitative 
measure of signal that can be inputted into scatter plots and histograms for description of the cellular 
population.94 This technique is quite powerful in describing the immunophenotype of leukocytes, and is 
highly applicable to the diagnosis and classification of ALL. 
By the mid 1950’s, before immunophenotyping was a reality, it was already clear that malignant 
cells were likely to have greater amounts of nucleic acid than normal cells, and this realization has 
continued to be demonstrated in many different tumor types.93,99'104 Aneuploidy was a common feature of 
many tumors, solid and hematological, and preliminary studies began to show that aneuploid cell lines and 
those with high S-phase fractions were predictive of poor outcome in a wide variety of tumors.96 The 
pattern of karyotypic instability that leads to spontaneous progression from normal euploid to aneuploid to 
neoplastic began to be elucidated.105 Intracellular flow cytometric studies can be applied to assay cellular 
DNA content, as well as some cytoplasmic markers. To conduct these assays, the cell membrane is first 
permeabilized using various detergents, alcohols, or paraformaldehyde. Subsequently, fluorochromes are 
introduced that stain the desired target. In the case of DNA, propidium iodide or eithidium bromide are 
commonly used as fluorescent stains after removal of RNA. As above, the cells are passed single-file 
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through the laser light source and levels of fluorescence are detected and quantified.94 This technique is 
useful in ALL as a method of determining DNA ploidy. 
The cell cycle consists of several phases including GapO (GO), Gapl (Gl), Synthesis (S), Gap2 
(G2), and Mitosis (M). The DNA content of cells is dependent on what phase of the cell cycle they are in. 
Cells in GO, Gl, and M phase are diploid (2n), whereas cells in G2 and at the end of S phase have a higher 
DNA content (4n).106 As mentioned before, neoplastic cells, including those of ALL, may have abnormal 
DNA content due to gain or loss of sets or fragments of chromosomes. This is known as aneuploidy, and it 
can be detected through the flow cytometric methods described above. DNA histograms can be derived 
from cytometric measures of DNA fluorescence in order to isolate the proportion of cells in different stages 
of the cell cycle and to quantify populations with abnormal DNA content. Using the data gathered from the 
cytometer, the percentage of aneuploid cells, the rate of proliferation of neoplastic cells (as represented by 
the proportion of cells in S, G2, and M phases), and the DNA index (the ratio of the DNA content of 
neoplastic cells to that of normal cells in the sample) can be described.94 
The use of flow cytometry for DNA index calculation lends great sensitivity and speed to this 
process. The technique is used widely for prognostic purposes once the diagnosis of ALL has been made, 
and it is simple and reliable. Along with the fact that a significant percentage of ALL cases exhibit 
aneuploid cell populations, these positive attributes make the use of DNA ploidy analysis an attractive 
consideration as a means to detect minimal residual disease. In the 20 to 40% of patients with aneuploidy, 
'the use of an “Lmmunophenotype-neutral” study, such as ploidy, may provide important additional 
information in MRD detection, especially if the case involves a B-lineage ALL without a unique 
phenotype. Because ploidy studies do not rely on markers that overlap between normal immature 
lymphoid precursors and leukemic blasts, they could potentially add specificity to flow cytometric 
immunophenotyping. This possibility forms the foundation of the question addressed in this report. The 
following is a retrospective analysis of all cases of ALL seen at our institution between 1991 and 2003. 
Flow cytometric immunophenotyping and DNA ploidy analysis were conducted on all patients initially, 
and in follow-up during treatment. We attempted to answer the question of whether flow cytometric DNA 




The purpose of this research project is to determine the utility, or lack thereof, of flow cytometric DNA 
ploidy analysis as a means of detecting minimal residual disease or early relapse among patients with 





Data regarding the flow cytometric analysis of peripheral blood and bone marrow from all patients 
diagnosed with ALL between 1991 and 2003 at Yale New Haven Hospital were retrieved from our 
hematopathology database using the Access application (Microsoft, Redmond, WA). Cases were identified 
using the query function and the search terms “ALL” and “Acute Lymphoblastic Leukemia”. This retrieval 
identified 114 pediatric and adult patients diagnosed with or followed-up for ALL at our institution during 
the specified time period. As a part of standard diagnostic procedure, flow cytometry had been utilized to 
determine the presence, immunophenotype, and DNA ploidy of neoplastic cells in samples from all patients 
identified. Results of DNA ploidy analysis and immunophenotyping of samples from days 14 to 28 and 
from post-remission studies were available through the database. Additional follow-up data regarding the 
occurrence of post-therapy or post-remission disease were obtained from patient files kept in the 
hematopathology department. The 114 patients were divided into four groups designated by 
immunophenotype and ploidy status: euploid with normal immunophenotype, euploid with aberrant 
immunophenotype, aneuploid with normal immunophenotype, and aneuploid with aberrant 
immunophenotype (table 1). 
Aneuploidy was defined as a DNA index greater or less than 1.0. “Normal” immunophenotypes 
were defined by expression of markers characteristic of precursor B-cells, regardless of signal intensity. 
This set of markers included CD 10, CD 19, CD45, CD34, and CD20. Patients were included in this group 
regardless of whether their leukemic clone normally expressed, overexpressed, or underexpressed these 
markers. Some authors have labeled ALL immunophenotypes with different quantitative expression patterns 
as aberrant since these variations are increasingly able to be identified using four-color flow cytometry18. We 
chose to include these ALL cases in the normal category in order to compare them with those expressing 
myeloid or T-lineage markers, which can be more reliably detected by flow cytometric methods. Due to the 





Peripheral blood and bone marrow specimens collected in ethylenediaminetetraacetic acid 
(EDTA) were analyzed using a FACScan cytometer (Becton Dickinson, San Jose, CA). Either three- or 
four-color immunofluorescence studies were performed using monoclonal antibodies to leukocyte CD 
markers conjugated to fluorescein isothionate (FITC), phycoerythrin (PE), peridinin chlorophyll protein 
(PerCP), Cy5.5, and allophycocyanin (APC). “Calibrate beads” in conjunction with FACSComp software 
(Becton Dickinson) were used to ensure adequate optical alignment and compensation within the flow 
cytometer. Isotype-matched negative controls conjugated to each fluorochrome were also employed in 
order to ensure proper function of reagents and absence of non-specific signal production. Initial diagnosis 
of ALL was conducted using a standard diagnostic panel of monoclonal antibodies. Although alterations in 
marker selection evolved over the period of time that the data were collected, the general approach included 
antibodies against CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD1 lb, CD13, CD14, CD16, CD19, CD20, 
CD33, CD34, CD41a, CD45, CD56, CD64, CD79a(c), CD117, myeloperoxidase, TdT, glycophorin, 
HLADr, and kappa and lambda light chains. Further distinction was provided with antibodies against 
cytoMu for those with pre-B ALL, and with anti-IgM, IgD, IgG, FMC7, CD23, CD1 lc, and CD43 for 
mature B-cell disease. Follow-up studies utilized custom panels specific to the initial leukemic 
immunophenotype. 
DNA Ploidy Analysis 
Cells isolated on Ficoll-Hypaque were fixed in ice-cold 70% methanol and exposed to lOOpg/ml 
of RNase in order to degrade any RNA present within the sample. The cells were then stained with a 
saturating concentration (40|ig/ml) of propidium iodide in order to fluorescence-label the sample DNA. 
Two aliquots of each sample were stained, and the second sample was mixed in a 1:1 ratio with normal 
human mononuclear cells that were processed identically and served as an internal standard. After staining, 
the samples were protected from light and analyzed within two hours. Flow cytometric ploidy analysis was 
performed with a FACScan flow cytometer using CellFIT software (Becton Dickinson). For each sample, 
1.5xl04 cells were analyzed. Single cells were distinguished from cell clumps by a doublet discrimination 
model utilizing pulse-area vs. pulse-width measures. The resulting DNA histograms were evaluated using 
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the SFIT mode. DNA index was calculated by dividing the modal fluorescence channel of the GoAj! peak 
of abnormal cells by the modal fluorescence channel of the residual Go/Gj normal cells present in the 
sample.107 
Mixing studies 
Cells from the human monocyte cell line U937 with a known mean DNA ploidy of 1.46 were 
obtained. These cells were then mixed in specific proportions with peripheral blood samples from patients 
with no hematologic abnormality and normal DNA ploidy. Six mixing proportions were utilized, including 
20.00%, 4.00%, 0.40%, 0.04%, 0.004%, and 0% U937 cells. These mixed samples with a known 
percentage of aneuploid cells were then subjected to DNA ploidy analysis as detailed above, such that a 
comparison could be made between the known and analytically determined percentage of aneuploid cells in 
each sample with a DNA index of 1.46. The standard cell cycle modeling program associated with our 
DNA ploidy analysis software was also utilized in order to determine if this would provide more accuracy 





DNA Ploidy Analysis 
One-hundred and fourteen patients were diagnosed or followed-up for ALL at our institution from 
1991 to 2003. An aneuploid population of cells was detected in the marrow or blood samples of 37 (32%) 
of these patients. Within this group, samples from 24 patients revealed leukemic clones with normal 
immunophenotypes, and samples from 13 patients revealed a clonal population with aberrant 
immunophenotype (table 1). Marrow specimens were monitored between days 14 to 28 and post-remission 
in most patients. 
The detection of MRD at these stages in patients with normal immunophenotypes is summarized 
in table 2. Patients 1-5 in table 2 experienced post-remission relapse. It is notable that DNA ploidy 
analysis revealed regenerated aneuploid populations of cells in all patients who relapsed. In fact, in all 
cases the percentage of non-erythroid marrow cells identified as aneuploid was higher than the percentage 
of cells identified as matching the original leukemic immunophenotype. Patients 1-3 were found to have 
less than 10% of cells expressing the original leukemic immunophenotype by flow cytometry at post¬ 
remission follow-up. Because these individuals presented with normal (i.e. non-unique) ALL 
immunophenotypes, these percentages are estimates. Due to similarity with normal B-cell precursors in 
post-therapeutic bone marrow, a definitive diagnosis of relapse could not be made by flow cytometric 
immunophenotyping alone without the presence of unusually high numbers of malignant cells. However, 
DNA ploidy analysis was effective in revealing the relapse in each of these three patients via the 
identification of significant percentages of aneuploid cells. 
Residual disease was detected in patients 6-8 at days 14 to 28. In this series, DNA ploidy analysis 
again showed higher percentages of aneuploid cells than flow cytometric percentages of presumably 
malignant cells. An exception was found in patient 7, where immunophenotyping revealed a slightly 
higher percentage of cells than did DNA ploidy analysis. However, in all cases where 
immunophenotyping revealed MRD, ploidy studies did so as well. In fact, in patient 6, 
immunophenotyping reported less than 5% leukemic cells, consistent with remission, while DNA ploidy 
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analysis demonstrated 8% aneuploid cells. In this case MRD could not be diagnosed with confidence by 
immunophenotyping, but was suggested by ploidy analysis. 
The presence of aneuploid DNA was useful in distinguishing neoplastic cells with normal 
immunophenotype in all patients with relapsed or residual disease. In certain cases, notably patients 1,2,3, 
and 6, the presence of a significant percentage of neoplastic cells could not be identified with confidence 
through immunophenotyping, largely due to the breakdown in specificity of the assay in the presence of B- 
cell precursors when the leukemic clone did not possess a unique phenotype. 
The detection of MRD at the aforementioned stages in patients with aberrant immunophenotypes 
is summarized in table 3. As the ALL cell phenotype was sufficiently unique in these patients, 
differentiation of residual and relapsed disease from “recovering” or normal precursor B-cells could be 
made with greater confidence compared to normal ALL immunophenotypes. Patients 1-6 experienced 
post-remission relapse, and in all cases DNA ploidy analysis detected a higher percentage of aneuploid 
cells than the percentage of cells detected with the original leukemic immunophenotype. In fact, in patients 
1 and 2 flow cytometric immunophenotyping detected no leukemic cells in the marrow and blood 
respectively both at day 14 and post-remission, while DNA ploidy analysis detected a small but distinct 
population of aneuploid cells in each case. These MRD and relapse events could only be predicted by 
DNA ploidy analysis and not by immunophenotyping. 
In patient 7 MRD was detected at day 14 by both immunophenotyping and DNA ploidy analysis. 
Again, the ploidy study demonstrated a higher percentage of aneuploid cells than immunophenotyping did 
of the original leukemic phenotype. This patient eventually went on to complete remission. 
DNA ploidy studies never failed to detect MRD or post-remission relapse when it was found by 
flow cytometric immunophenotyping, whether or not the leukemic cells expressed aberrant markers. In all 
cases but one, ploidy analysis revealed a higher percentage of abnormal, and likely neoplastic, cells than 
did immunophenotyping. Additionally, in several cases ploidy analysis was sensitive enough to reveal 




Mixing experiments were performed for the purpose of quantifying the sensitivity of the DNA 
ploidy analysis technique used in the study (table 4). At the highest percentage of aneuploid cell mixing, 
DNA ploidy analysis was within 0.5% of the true mixing proportion. As the percentage of aneuploid cells 
was reduced in the mixture, the results were variable, progressing from 1.28% to 0.18% to 0.03% to 0.65% 
to 0.04% difference between known and analytically determined aneuploid cell percentages. Modeling 
software, intended to correct for cell cycle variations that may lead to false-positive identification of 
aneuploidy, was utilized in tandem with the standard mixing study calculations. At the two highest mixing 
proportions, the software allowed for 0.33% and 0.87% difference between known and analytically 
determined aneuploid cell percentages. However, the program failed after addition of less than 1% U937 
cells to the sample, indicating a potential lack of utility when the population of aneuploid cells is small. 
Based on these data, it would appear that DNA ploidy analysis using current techniques should achieve a 




The prognostic importance of MRD detection in ALL is quite clear. Presence or absence and 
quantity of residual leukemia affects outcome and relapse incidence significantly, regardless of other risk 
factors. Flow cytometric immunophenotyping is a rapid, sensitive and accurate method of assessing MRD 
status, but it suffers from an area of decreased specificity in the realm of B-lineage ALL cases. Similarity 
between leukemic blasts and normal lymphoid precursors in the regenerating bone marrow can cloud 
immunophenotypic distinction of normal from malignant cells. In light of this, our study sought to 
investigate whether follow-up DNA ploidy analysis could detect MRD or relapse in patients with B-lineage 
ALL who had aneuploid cell populations identified at diagnosis. We anticipated that this technique would 
be especially useful for following patients with non-aberrant immunophenotypes that were similar to 
normal precursor B-cells. 
Our retrospective analysis of cases of B-lineage ALL at Yale New Haven Hospital over the last 12 
years revealed 114 patients, 37 (32%) of whom displayed aneuploid cell populations by non-unity DNA 
index at diagnosis. We were able to identify post-remission relapse or MRD in 15 patients from this group, 
7 with aberrant and 8 with normal immunophenotypes. 
For those with normal immunophenotype, an aneuploid cell population was always detected when 
immunophenotyping identified residual disease or relapse. The congruence of results between these two 
methods lends confidence to the idea that they are both measuring the same population of malignant cells. 
It would be expected that a regenerating malignant clone originally identified as aneuploid would return 
with the same altered genetic status. In addition, this congruence suggests that ploidy analysis has at least 
the same degree of sensitivity as immunophenotyping. In fact, in all but one case, the percentage of 
malignant cells detected by ploidy exceeded the percentage detected by immunophenotyping, suggesting 
that ploidy analysis may possess greater sensitivity that immunophenotyping. In this group of patients, 
ploidy identified on average >8% more detectable malignant cells than did immunophenotyping, with the 
maximum difference reaching 18%. This increased level of detection led to three cases in which ploidy 
was able to make the diagnosis of relapse and one case in which it was able to detect MRD while 
immunophenotyping could not do so with sufficient confidence. These cases serve as examples of the 
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difficulty created by B-cell precursors in regenerating bone marrow. While some degree of a possibly 
neoplastic cell population was detectable by immunophenotyping, the extent of the potential clone could 
only be estimated, due to the fact that malignant cells could not be well-distinguished from normal 
immature lymphoid cells. Ploidy, on the other hand, detects malignant cells based on a relatively simple 
clonal characteristic that should not be exhibited by normal marrow constituents. The addition of ploidy 
analysis allowed for detection of recurrent disease that could have been dismissed using only 
immunophenotyping in 3 of 5 relapse cases in this group. The same can be said of 1 of 3 cases of MRD. 
This is a significant improvement in the sensitive and specific detection of MRD and relapse that could 
potentially be harnessed to provide patients with appropriate early intervention. 
For ALL cases with an aberrant immunophenotype, which attenuates the difficulties associated 
with confusion of lymphoid precursors with blasts, ploidy analysis continued to be a useful tool. Again, 
detection was congruent between ploidy and immunophenotyping in all cases, suggesting that each 
technique is measuring the same population of malignant cells. In this group, ploidy detected higher 
percentages of malignant cells than immunophenotyping in every case. On average, ploidy detected almost 
10% more neoplastic cells than immunophenotyping, and in one case ploidy detected 33% more abnormal 
cells, suggesting a potentially greater sensitivity. In two cases, ploidy analysis detected small but 
identifiable proportions of malignant cells at both day 14 and post-remission when immunophenotyping 
detected no abnormal cells at all. These data demonstrate a potential utility for DNA ploidy studies even in 
B-lineage ALL cases with aberrant immunophenotype. 
This is the first investigation of whether DNA ploidy analysis is a useful tool in the detection of 
MRD in ALL patients. The use of ploidy appears, based on our results, to lend some degree of sensitivity 
and specificity to MRD and relapse monitoring for individuals with ALL. We have demonstrated several 
circumstances in which confident diagnosis of MRD or relapse could not be made by immunophenotyping, 
but where identification of an aneuploid cell population served to confirm the presence of malignant cells. 
Beyond this, initial results would suggest that ploidy may be a more sensitive means of detecting residual 
or regenerated leukemic cells. It should be noted that 5 of the 15 patients had immunophenotyping and 
ploidy analysis performed on peripheral blood rather than bone marrow. In terms of comparing detection 
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methods, the pattern of results obtained with these samples mirrored those obtained from marrow samples. 
This suggests that ploidy studies are applicable to peripheral as well as intramedullary sampling. 
Mixing studies were carried out using the U937 human monocyte cell line and normal peripheral 
blood samples in an attempt to better define the sensitivity of DNA ploidy analysis. The results 
demonstrate that, in spite of an apparently greater sensitivity suggested by increased quantitative detection 
of aneuploid cells as described above, DNA ploidy analysis may in fact be intrinsically less sensitive than 
immunophenotyping. Based on the data from this study, a sensitivity of 0.5% to 1.0% may be expected 
with ploidy analysis, relative to the well documented standard of 0.1% to 0.5% provided by 
immunophenotypic studies. The principal limitation to sensitivity in ploidy analysis is that some degree of 
aneuploidy is always present in normal blood or marrow. At any given time, a certain number of cells will 
be in S-phase, and will consequently exhibit a variable DNA index between 1.0 and 2.0, which would 
mimic an aneuploid leukemic clone. The final mixing experiment in table 4 demonstrates this, showing 
that cells in the peripheral blood with a DNA index of 1.46 are present at a level of 0.04%. This effect may 
be amplified in the marrow, where hematopoeisis is prominent. Cell cycle influences may be attenuated to 
some extent by using commercially available modeling programs. However, this technology was largely 
unsuccessful in eliminating the discrepancy in our mixing studies, especially when the percentage of 
aneuploid cells was low. One additional caveat is that the sensitivity of ploidy analysis is partly dependent 
on the coefficient of variation (CV) of the aneuploid peak on the DNA histogram. The CV is tighter for 
leukemic clones than it is for aneuploid cell lines, such as the one we used. Thus, the sensitivities predicted 
by the mixing data may be slightly better in actual patient samples where leukemic cells are present, but 
this effect would likely be small. Therefore, at this point in time, there is a boundary to sensitivity in DNA 
ploidy analysis. While such a limitation does appear to prevent the technology from surpassing the 
sensitivity of immunophenotyping, it does not eliminate the utility of the technique. As describe above, 
ploidy analysis continues to identify significant aneuploid cell populations when immunophenotyping 
cannot be entirely relied upon. In addition, the significantly greater percentage of aneuploid cell detection 
by ploidy analysis is not necessarily explained entirely by the presence of S-phase cell populations. What 
is clear, however, is that the higher percentages of aneuploid cells detected by ploidy studies likely do not 
indicate that the technique has a higher sensitivity. 
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The most obvious weakness in this study is its small sample size. In spite of retrieving 12 years of 
data, only 114 ALL patients were identified, with 37 patients exhibiting aneuploid cell populations and 15 
of these showing MRD or relapse. Clearly, it is difficult to draw broad conclusions from such a small 
amount of presented data. However, the congruity and uniformity of results across immunophenotype, age, 
and sampling location does lend credence to ploidy analysis as a useful technique in MRD detection. 
Another drawback is the retrospective study design, although gaining sufficient sample size prospectively 
would have been a difficult proposition. Additionally, only two monitoring periods were included for 
analysis. Most reports describing MRD prognosis utilize at least 5 time-points, either during or after 
chemotherapy, for analysis. More data points could have been useful in this study in order to identify 
clearer trends in consistency between ploidy and immunophenotyping and to document other examples of 
the success or failure of ploidy analysis to detect disease more sensitively. It would also be beneficial, with 
sufficient sample size, to separate patients being monitored from peripheral versus marrow sites into 
separate groups in order to further standardize comparison and prevent confounding in either direction. 
Some work has shown that MRD detection of B-lineage ALL by immunophenotyping using peripheral 
blood is not concordant with marrow sampling. Not surprisingly, positive marrow samples are not always 
accompanied by a positive blood sample, and blood-positivity is associated with a very high risk of disease 
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recurrence. 
Many of these weaknesses could be remedied through further investigation using larger sample 
sizes that not only will provide statistical power, but can be subdivided further and subjected to multivariate 
analyses. Preferably, such studies would be conducted prospectively along with treatment protocols and 
would involve sample assessment at multiple time intervals. In light of the widespread use of PCR for 
MRD detection, it may also be of interest to compare the sensitivity of DNA ploidy analysis with that of 
PCR amplification. It is likely that such a study could only be completed by one of the larger cooperative 
cancer groups, such as the Children’s Oncology Group (COG). 
Beyond difficulties with the study design, DNA ploidy analysis itself has limitations for the 
purposes of MRD detection. First and foremost, this technique is only applicable to patients with 
detectable aneuploid cell populations at diagnosis. While all patients may be investigated for the presence 
of aneuploidy as a matter of initial prognostication, only about 30% of patients will have identifiable 
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aneuploid populations that can be utilized for follow-up. Additionally, it is not entirely understood whether 
other events besides re-emergence of a leukemic clone can lead to detection of an increased marrow or 
peripheral blood DNA index. If other stimuli to aneuploidy exist, it will be necessary to determine whether 
or not they could confound the use of ploidy analysis in the current context. There is some allegiance 
among clinicians to the use of either flow cytometric immunophenotyping or PCR for MRD detection, and 
even without preference, some institutions have access to only one method. This again could be a 
hindrance to the wide applicability of ploidy analysis, as it will be limited to those settings where a flow 
cytometer is available and scrupulously maintained. 
In spite of its possible limitations, DNA ploidy analysis appears to be a useful technique for 
detection of relapse or MRD among many patients with B-lineage ALL. Although our sample is small, the 
presented data indicate that ploidy analysis is capable of detecting residual or relapsed leukemia 
consistently when compared with immunophenotyping. Ploidy appeared to be a useful, and possibly 
superior, indicator of relapse or MRD whether or not the leukemic clone exhibited an aberrant 
immunophenotype, thus exceeding the expectations of our study question. Hopefully these results will be 
repeated in larger trials, and future patients will be able to benefit from an additional technique to detect 
unwanted leukemic cells and facilitate effective therapy. 
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Table 1. ALL patients (n=l 14) grouped according to immunophenotype (normal vs aberrant), DNA ploidy, 
















50 27 24 13* 
Diagnosis 
* In one case, two aneuploid populations were detected (15% with a DNA index of 0.66 and 70% with a 
DNA index of 1.32) 
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Table 2: Laboratory data from patients with a normal ALL immunophenotype and aneuploid neoplastic 
cells 
Day 14-28 marrow Post-remission Status 
Age/Sex Initial specimen DNA Index % by IP % aneuploid % by IP % aneuploid 
1 11/F Marrow 0.61 ND ND <10* 15 
2 3/M Marrow 1.43 0 0 <5* 15 
3 35/F Marrow 1.19 ND ND <10* 28 
4 10/F Marrow 1.09 ND ND >90 >90 
5 71/M ND 
0.79** ND ND 40 48 
6 9/M Marrow 1.13 <5 8 RM RM 
7 7/F Blood 1.24 20 17 RM RM 
8 3/F Blood 
1.14 40 57 RM RM 
9 59/F Marrow 
1.12 0 0 RM RM 
10 2/M Marrow 
1.16 0 0 RM RM 
11 6/F Marrow 
1.17 ND ND RM RM 
12 15m/M Blood 
1.27 ND ND RM RM 
13 3/M Marrow 
1.17 ND ND RM RM 
14 51/F Marrow 
0.76 0 0 RM RM 
15 15/M Marrow 1.15 0 0 RM RM 
16 7/F Marrow 1.25 0 0 RM RM 
17 2/F Marrow 
1.18 ND ND RM RM 
18 3/F Marrow 
1.21 ND ND RM RM 
19 4/F Marrow 1.19 0 0 RM RM 
20 2/F Marrow 1.17 ND ND RM RM 
21 1/F Blood 1.35 0 0 RM RM 
22 3/F Blood 1.14 0 0 RM RM 
23 5/M Marrow 1.08 ND ND RM RM 
24 3/F Marrow 1.19 ND ND RM RM 
*Since the ALL immunophenotype was not unique, these percentages are only estimates and the diagnose 
could not be determined with confidence by immunophenotype alone 
**This value represents the DNA index identified at relapse, no data was available prior to relapse for this 
patient 
ND = No Data available 
RM = Remission 
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Table 3: Laboratory data from patients with an aberrant ALL immunophenotype (CD33+ and/or CD 13+) 
and aneuploid neoplastic cells 
Day 14 marrow Post-remission status 
Initial DNA % by IP % aneuploid % by IP % aneuploid 
Age/Sex specimen Index 
1 20/F Marrow 
0.63 0 2 0 4 
2 13/F Blood 
0.56 0 5 0 2 
3 
14/M Marrow 
0.66/1.32* 0 0 57 90 
4 3/M Blood 
1.21 0 0 31 52 
5 4/M Marrow 
1.22 0 0 51 72 
6 14/M Marrow 
1.22 ND ND 93 96 
7 57/M Blood 
1.22 15 20 RM RM 
8 19/M Blood 
1.08 ND ND RM RM 
9 7/M Marrow 
1.19 0 0 RM RM 
10 5/F Marrow 
1.21 ND ND RM RM 
11 14/M Blood 
1.22 ND ND RM RM 
12 4/M Marrow 
1.82 ND ND RM RM 
13 6/F Marrow 
1.18 ND ND RM RM 
*Two aneuploid populations were detected (15% with a DNA index of 0.66 and 70% with a DNA 
index of 1.32); only the hyperdiploid population was detected at relapse. 
ND = No Data available 
RM = Remission 
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Table 4. Mixing study data 
%U937 cells mixed in blood 
% determined by DNA ploidy 
analysis 
% determined by modeling 
program 
20.00% 20.50% 20.67% 
4.00% 2.72% 3.13% 
0.40% 0.22% Unsuccessful 
0.04% 0.07% Unsuccessful 
0.004% 0.06% Unsuccessful 
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